Literature DB >> 24603949

[Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy].

L Deutschenbaur1, M Lambert, M Walter, D Naber, C G Huber.   

Abstract

Schizophrenia spectrum disorders (SSD) constitute a group of psychiatric illnesses which frequently lead to persisting mental impairment. Although some patients show a clinical course with few episodes and good long-term outcome, the course of the disease is often chronic and unfavorable. Long-term treatment (LTT) of SSD pertains to the postacute stabilization period and the remission period following pharmacological and psychosocial therapy of an acute illness episode. This article provides an overview of treatment recommendations concerning long-term pharmacotherapy, dealing with side effects, treatment of non-response and therapy resistance and the treatment of psychiatric comorbidities. Furthermore, an overview of non-pharmacological treatment options is presented. An integrated therapeutic setting combining evidence-based pharmacotherapy, psychosocial interventions, and supportive therapies is recommended for optimal LTT of SSD. Considering the limited financial resources available in the healthcare system, one of the major challenges is to provide patients with access to the evidence-based treatment options available.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24603949     DOI: 10.1007/s00115-013-3807-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  44 in total

1.  Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial).

Authors:  Martin Lambert; Thomas Bock; Daniel Schöttle; Dietmar Golks; Klara Meister; Liz Rietschel; Alexandra Bussopulos; Marietta Frieling; Michael Schödlbauer; Marc Burlon; Christian G Huber; Gunda Ohm; Manoshi Pakrasi; Michael Sadre Chirazi-Stark; Dieter Naber; Benno G Schimmelmann
Journal:  J Clin Psychiatry       Date:  2010-03-23       Impact factor: 4.384

2.  Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years.

Authors:  M Álvarez-Jiménez; J F Gleeson; L P Henry; S M Harrigan; M G Harris; E Killackey; S Bendall; G P Amminger; A R Yung; H Herrman; H J Jackson; P D McGorry
Journal:  Psychol Med       Date:  2011-08-19       Impact factor: 7.723

Review 3.  Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.

Authors:  Paolo Fusar-Poli; Matthew J Kempton; Robert A Rosenheck
Journal:  Int Clin Psychopharmacol       Date:  2013-03       Impact factor: 1.659

Review 4.  Effects of psychoactive substances in schizophrenia -- findings of structural and functional neuroimaging.

Authors:  M Walter; N Denier; M Vogel; U E Lang
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

5.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.

Authors:  Lex Wunderink; Roeline M Nieboer; Durk Wiersma; Sjoerd Sytema; Fokko J Nienhuis
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

Review 6.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 7.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

Review 8.  Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

Authors:  Noam Y Kirson; Peter J Weiden; Sander Yermakov; Wayne Huang; Thomas Samuelson; Steve J Offord; Paul E Greenberg; Bruce J O Wong
Journal:  J Clin Psychiatry       Date:  2013-04-19       Impact factor: 4.384

9.  Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.

Authors:  Robin Emsley; Petrus P Oosthuizen; Liezl Koen; Dana J H Niehaus; Guadalupe Martinez
Journal:  J Clin Psychiatry       Date:  2012-04       Impact factor: 4.384

10.  Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.

Authors:  Eirik Kjelby; Hugo A Jørgensen; Rune A Kroken; Else-Marie Løberg; Erik Johnsen
Journal:  BMC Psychiatry       Date:  2011-08-31       Impact factor: 3.630

View more
  2 in total

Review 1.  Could Animal-Assisted Therapy Help to Reduce Coercive Treatment in Psychiatry?

Authors:  Sonja Widmayer; Stefan Borgwardt; Undine E Lang; Christian G Huber
Journal:  Front Psychiatry       Date:  2019-11-14       Impact factor: 4.157

2.  Approval of Coercion in Psychiatry in Public Perception and the Role of Stigmatization.

Authors:  Sahar Steiger; Julian Moeller; Julia F Sowislo; Roselind Lieb; Undine E Lang; Christian G Huber
Journal:  Front Psychiatry       Date:  2022-01-07       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.